Alastair Southwell

Alastair Southwell

Partner - BSc

Alastair brings 25 years of strategic planning and product commercialization experience across multiple disease areas in big pharma and start up environments. His consulting practice areas of focus are product strategy, launch planning, asset valuation, business development and portfolio review.

Professional Background

Alastair brings 25 years of strategic planning and product commercialization experience in big pharma and start up environments. He has broad therapeutic area knowledge, and expertise in product strategy, launch planning, asset valuation, business development and portfolio review.

Most recently, he worked at a NASDAQ listed biotech company which discovered and developed small molecule GPCR drugs for CNS indications. As Commercial Director he was latterly responsible for product strategy and planning key elements of the launch for an IV hospital drug for acute pain management. During his time there Alastair’s responsibilities also included roles in business development, asset valuation, portfolio review, insight and analytics, and corporate communications.

He spent 15 years with GSK and its parent companies in both business planning and product strategy roles. As Commercial Director in the external drug discovery unit (a BD function), Alastair was part of a team that closed option-based licensing deals on more than 30 drug development programs for GSK in oncology, CNS, inflammatory, metabolic, and rare diseases. He also spent time in strategic planning roles for the GSK genetics directorate, the biopharmaceuticals business unit, and in drug discovery portfolio review. Alastair had roles of increasing responsibility in business analytics for several therapeutic development franchises at GlaxoWellcome and Glaxo.

Alastair started his career as a Management Consultant with Arthur D Little. He holds a BSc in biochemistry from Imperial College, University of London, UK.

Recent consulting projects include:

    • For a US biotech developing novel therapies for rare genetic endocrine disorders, detailing a plan for the design and build of a commercial data infrastructure to support product launch.
    • For a pre-commercial US pharma in the CNS space, supporting corporate strategy and developing revenue forecasts for its pipeline drugs in acute pain, migraine, neuropathic pain, and depression.
BACK